Table 1 Patient characteristics of the microarray cohort (n = 36 GBMs) and the validation cohort (n = 142 IDH1 wt GBMs), presented by location-dependent groups I–IV

 Patients, n (%)

11 (30)

6 (17)

10 (28)

9 (25)

36

 Sex, n (male : female)

5 : 6

6 : 0

7 : 3

5 : 4

23 : 13

0.14^a

 Age at diagnosis, mean (years)

68

64

59

64

65

0.21^b

 Extent of resection, n (%)

0.85^a

  - Complete

3 (27)

2 (33)

4 (40)

2 (22)

11 (31)

  - Partial

4 (36.5)

4 (67)

5 (50)

5 (56)

18 (50)

  - Unknown

4 (36.5)

0

1 (10)

2 (22)

7 (19)

 OS, median (months)

9

9.5

15

16

11.5

0.98^c

 PFS, median (months)

3

5.5

3

5

3.5

0.47^c

 Multifocal CE lesion, n (%)

2 (18)

0 (0)

1 (10)

0 (0)

3 (8)

0.42^a

 Multifocal FLAIR lesion, n (%)

2 (18)

0 (0)

3 (30)

0 (0)

5 (14)

0.19^a

 MGMT promoter methylation, n (%)

0.06^a

  - Yes

9 (82)

1 (17)

6 (60)

4 (44)

20 (56)

  - No

2 (18)

5 (83)

4 (40)

5 (56)

16 (44)

 IDH1 mutation, n (%)

0.44^a

  - Yes

0

0

1 (10)

0

1 (3)

  - No

11 (100)

6 (100)

9 (90)

9 (100)

35 (97)

 Patients, n (%)

49 (35)

17 (12)

66 (46)

10 (7)

142

 Sex, n (male : female)

31 : 18

9 : 8

41 : 25

6 : 4

87 : 55

0.89^a

 Age at diagnosis, mean (years)

62

57

62

64

62

0.32^d

 KPS preoperative, mean

78

76

86

86

82

0.01 ^d

 Extent of resection, n (%)

0.006 ^a

  - Complete

8 (16)

6 (35)

23 (35)

7 (70)

44 (31)

  - Partial

37 (76)

9 (53)

31 (47)

2 (20)

79 (56)

  - Unknown

4 (8)

2 (12)

12 (18)

1 (10)

19 (13)

 Radiation therapy, n (%)

43 (88)

16 (94)

62 (94)

8 (80)

129 (91)

0.4^a

 Temozolomide, n (%)

30 (61)

14 (82)

43 (65)

8 (80)

95 (67)

0.33^a

 OS, median (months)

12

14

15

17

13

0.004 ^c

 PFS, median (months)

6

8

7

8

7

0.27^c

 Censored patients, n (%)

2 (4)

1 (6)

4 (6)

0 (0)

7 (5)

0.85^a

 MGMT promoter methylation

0.43^a

  - Yes, n (%)

10 (20)

7 (41)

17 (26)

4 (40)

38 (26)

  - No, n (%)

16 (33)

6 (35)

27 (41)

3 (30)

52 (37)

  - Unknown, n (%)

23 (47)

4 (24)

22 (33)

3 (30)

52 (37)

 IDH1 mutation, n (%)

N/A

  - No, n (%)

49 (100)

17 (100)

66 (100)

10 (100)

142(100)